v3.22.4

Collaboration and License Agreements - Pfizer Collaboration and License Agreement (Details) - USD ($)		1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 26, 2020	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022	Jul. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds received from license agreement milestone	$ 146,400,000		$ 0
Amounts due to Pfizer			25,768,000	$ 25,768,000		$ 32,563,000
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of revenue recognized	100.00%
Upfront payment received		$ 650,000,000
Proceeds received from license agreement milestone	$ 150,000,000		100,000,000
Maximum payment from milestones achieved	3,800,000,000
Maximum payment from regulatory milestones achieved	100,000,000						$ 100,000,000
Maximum aggregate payment from milestones achieved	200,000,000
Maximum payment from sales-related milestones achieved	$ 3,500,000,000
Costs covered by company				50,000,000	$ 100,000,000
Repayment period	2 years
Reduction in cost share advance from implied financing costs	$ 3,600,000
Deferred revenue, recognition period	6 years
Amounts due to Pfizer			25,800,000	25,800,000		32,600,000
Amounts due to collaboration partner, share of profits			$ 26,800,000	$ 26,800,000		$ 14,100,000
Percentage of revenue recognized by counterparty			50.00%	50.00%		50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses			$ 1,000,000	$ 1,000,000		$ 18,500,000
Reimbursement of allowable expenses (as a percent)			50.00%	50.00%		50.00%
Reimbursement of total expenses (as a percent)			100.00%	100.00%

Accrued Liabilities, Collaboration Agreement, Current

+ References

No definition available.

+ Details

Name:	myov_AccruedLiabilitiesCollaborationAgreementCurrent
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Accrued Liabilities, Collaboration Agreement, Reimbursement of Expenses, Current

+ References

No definition available.

+ Details

Name:	myov_AccruedLiabilitiesCollaborationAgreementReimbursementOfExpensesCurrent
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Accrued Liabilities, Collaboration Agreement, Share of Profits, Current

+ References

No definition available.

+ Details

Name:	myov_AccruedLiabilitiesCollaborationAgreementShareOfProfitsCurrent
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Agreement Costs, Reimbursements Covered by Company, Amount

+ References

No definition available.

+ Details

Name:	myov_CollaborativeArrangementAgreementCostsReimbursementsCoveredByCompanyAmount
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Arrangement, Agreement Costs, Reimbursements Covered by Company, Repayment Period

+ References

No definition available.

+ Details

Name:	myov_CollaborativeArrangementAgreementCostsReimbursementsCoveredByCompanyRepaymentPeriod
Namespace Prefix:	myov_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Liability, Costs Recognized as Financing Costs

+ References

No definition available.

+ Details

Name:	myov_CollaborativeArrangementLiabilityCostsRecognizedAsFinancingCosts
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, Percentage of Reimbursement of Allowable Expenses

+ References

No definition available.

+ Details

Name:	myov_CollaborativeArrangementPercentageOfReimbursementOfAllowableExpenses
Namespace Prefix:	myov_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Percentage of Revenue Recognized

+ References

No definition available.

+ Details

Name:	myov_CollaborativeArrangementPercentageOfRevenueRecognized
Namespace Prefix:	myov_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Percentage of Revenue Recognized by Counterparty

+ References

No definition available.

+ Details

Name:	myov_CollaborativeArrangementPercentageOfRevenueRecognizedByCounterparty
Namespace Prefix:	myov_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Percentage of Total Allowable Expenses

+ References

No definition available.

+ Details

Name:	myov_CollaborativeArrangementPercentageOfTotalAllowableExpenses
Namespace Prefix:	myov_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Deferred Revenue, Recognition Period

+ References

No definition available.

+ Details

Name:	myov_DeferredRevenueRecognitionPeriod
Namespace Prefix:	myov_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement, Milestones, Maximum, Value

+ References

No definition available.

+ Details

Name:	myov_LicenseAgreementMilestonesMaximumValue
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License Agreement, Regulatory Milestones, Maximum, Aggregate Value

+ References

No definition available.

+ Details

Name:	myov_LicenseAgreementRegulatoryMilestonesMaximumAggregateValue
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License Agreement, Regulatory Milestones, Maximum, Value

+ References

No definition available.

+ Details

Name:	myov_LicenseAgreementRegulatoryMilestonesMaximumValue
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License Agreement, Sales-Related Milestones, Maximum, Value

+ References

No definition available.

+ Details

Name:	myov_LicenseAgreementSalesRelatedMilestonesMaximumValue
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Proceeds from Collaborators and License Fees Received

+ References

No definition available.

+ Details

Name:	myov_ProceedsFromCollaboratorsAndLicenseFeesReceived
Namespace Prefix:	myov_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=myov_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Myovant Sciences Ltd. 10-Q